The stock of SILO Pharma Inc (SILO) has gone up by 2.19% for the week, with a 43.90% rise in the past month and a -53.94% drop in the past quarter. The volatility ratio for the week is 1.81%, and the volatility levels for the past 30 days are 5.78% for SILO. The simple moving average for the past 20 days is 8.98% for SILO’s stock, with a -43.77% simple moving average for the past 200 days.
Is It Worth Investing in SILO Pharma Inc (NASDAQ: SILO) Right Now?
Moreover, the 36-month beta value for SILO is 1.57. Analysts have varying opinions on the stock, with 1 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for SILO is 6.11M and currently, short sellers hold a 4.16% of that float. On June 25, 2025, SILO’s average trading volume was 939.37K shares.
SILO) stock’s latest price update
The stock of SILO Pharma Inc (NASDAQ: SILO) has decreased by -0.10 when compared to last closing price of 0.62.Despite this, the company has seen a gain of 2.19% in its stock price over the last five trading days. globenewswire.com reported 2025-06-25 that Technology Co-Developed by the U.S. Department of Veterans Affairs and Emory University NEW YORK, June 25, 2025 (GLOBE NEWSWIRE) — Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, today announced that it has entered into a non-binding letter of intent to form a strategic 50:50 joint venture with Hoth Therapeutics, Inc. (Nasdaq: HOTH) to develop and commercialize a potential treatment for obesity and metabolic disease based on technology Hoth has exclusively licensed from the U.S. Department of Veterans Affairs (VA) that was co-developed by the VA and Emory University. The novel therapeutic platform centers on glial cell line-derived neurotrophic factor (GDNF), a VA-invented biologic with demonstrated anti-obesity effects and metabolic regulation in preclinical models.
SILO Trading at -13.88% from the 50-Day Moving Average
After a stumble in the market that brought SILO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -86.28% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at SILO starting from Weisblum Eric, who purchase 10,000 shares at the price of $0.43 back on May 27 ’25. After this action, Weisblum Eric now owns 197,932 shares of SILO Pharma Inc, valued at $4,329 using the latest closing price.
Weisblum Eric, the CEO and President of SILO Pharma Inc, purchase 2,500 shares at $0.84 during a trade that took place back on Dec 13 ’24, which means that Weisblum Eric is holding 187,932 shares at $2,097 based on the most recent closing price.
Stock Fundamentals for SILO
Current profitability levels for the company are sitting at:
- -68.24 for the present operating margin
- 0.92 for the gross margin
The net margin for SILO Pharma Inc stands at -64.11. The total capital return value is set at 5.53. Equity return is now at value -99.38, with -72.00 for asset returns.
Currently, EBITDA for the company is -4.38 million with net debt to EBITDA at 0.66. When we switch over and look at the enterprise to sales, we see a ratio of 18.24. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.73.
Conclusion
To wrap up, the performance of SILO Pharma Inc (SILO) has been mixed in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
